PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Vabicaserin in Subjects With Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 199
- Registration Number
- NCT00563706
- Locations
- 🇨🇦
Pfizer Investigational Site, Kingston, Ontario, Canada
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Phase 3
Terminated
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Biological: 13vPnC
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 271
- Registration Number
- NCT00562354
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00562120
- Locations
- 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
Phase 2
Withdrawn
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: PNU-165442G; [S,S]-reboxetine
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00562055
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 951
- Registration Number
- NCT00561951
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
Phase 2
Completed
- Conditions
- Colorectal Neoplasm
- Interventions
- Biological: CP-751, 871
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 168
- Registration Number
- NCT00560560
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00560573
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00560235
- Locations
- 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00559910
- Locations
- 🇬🇧
Pfizer Investigational Site, Edinburgh, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath